A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer chemotherapy …, 2013 - Springer
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
[PDF][PDF] A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin Ò) in cancer patients
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer Chemother …, 2013 - researchgate.net
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
金井 - Cancer chemotherapy and pharmacology, 2013 - cir.nii.ac.jp
抄録 A growing number of preclinical studies have demonstrated that curcumin could be a
promising anticancer drug; however, poor bioavailability has been the major obstacle for its …
promising anticancer drug; however, poor bioavailability has been the major obstacle for its …
[引用][C] A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
M KANAI, Y OTSUKA, Y MURAKAMI… - Cancer …, 2013 - pascal-francis.inist.fr
A phase I study investigating the safety and pharmacokinetics of highly bioavailable
curcumin (Theracurmin®) in cancer patients CNRS Inist Pascal-Francis CNRS Pascal and …
curcumin (Theracurmin®) in cancer patients CNRS Inist Pascal-Francis CNRS Pascal and …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer …, 2013 - europepmc.org
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
[PDF][PDF] A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
M Kanai, E Hatano, S Matsumoto, H Shibata - Cancer Chemother …, 2013 - Citeseer
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer …, 2013 - search.ebscohost.com
Background: A growing number of preclinical studies have demonstrated that curcumin
could be a promising anticancer drug; however, poor bioavailability has been the major …
could be a promising anticancer drug; however, poor bioavailability has been the major …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
M Kanai, Y Otsuka, K Otsuka, M Sato… - Cancer Chemotherapy …, 2013 - infona.pl
Background A growing number of preclinical studies have demonstrated that curcumin could
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
be a promising anticancer drug; however, poor bioavailability has been the major obstacle …
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
M Kanai, Y Otsuka, K Otsuka… - Cancer …, 2013 - repository.kulib.kyoto-u.ac.jp
A growing number of preclinical studies have demonstrated that curcumin could be a
promising anticancer drug; however, poor bioavailability has been the major obstacle for its …
promising anticancer drug; however, poor bioavailability has been the major obstacle for its …